Aspen Pharmacare Holdings (APN.JO) Aandeel Koers
Aspen Pharmacare Holdings Koers
In de afgelopen 19 jaar liet Aspen Pharmacare Holdings de omzet jaarlijks met 12,0% groeien tot 34,87 Miljard ZAR. De winst per aandeel is de afgelopen 19 jaar met 6,1% per jaar gegroeid. Bij Aspen Pharmacare Holdings is de nettowinstmarge met 7,6% ten opzichte van 16,8% enkele jaren geleden gedaald. Op de huidige koers komt het dividendrendement uit op ongeveer 1,28%. De uitkeringsratio ligt rond 28% van de winst. Het dividend is de afgelopen 19 jaar met 6,1% per jaar gegroeid. Het consensus-koersdoel voor Aspen Pharmacare Holdings op 12 maanden bedraagt 117,30 ZAR, circa 28,7% onder de huidige koers. Van de 10 analisten geven 0 het aandeel een koopadvies — per saldo een Houden-consensus.
Aspen Pharmacare Holdings aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Aspen Pharmacare Holdings bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Aspen Pharmacare Holdings
The business model of Aspen Pharmacare Holdings Ltd is focused on the manufacturing and marketing of pharmaceutical and healthcare products. Aspen Pharmacare is a leading global supplier of branded and generic pharmaceuticals, as well as infant nutritionals and consumer healthcare products. With a diverse portfolio of products, the company operates across multiple therapeutic areas including anaesthetics, thrombosis, oncology, and respiratory. Aspen Pharmacare also engages in extensive research and development activities to drive innovation within the pharmaceutical industry. Its commitment to quality and affordability ensures the availability of essential medicines to a wide range of markets worldwide.
Aspen Pharmacare Holdings Ltd is primarily active in the pharmaceutical industry.
The main competitors of Aspen Pharmacare Holdings Ltd in the market are Teva Pharmaceutical Industries Ltd, Mylan N.V., and Sun Pharmaceutical Industries Ltd.
Aspen Pharmacare Holdings Ltd, commonly known as Aspen, is a leading global pharmaceutical company with a rich history and strong background. Founded in 1850 and headquartered in Durban, South Africa, Aspen has grown into a reputable player in the healthcare industry. The company specializes in the manufacturing and distribution of both branded and generic pharmaceutical products across various therapeutic areas. With a diversified portfolio, Aspen operates in more than 150 countries, serving patients and healthcare professionals worldwide. Over the years, Aspen has made strategic acquisitions and formed partnerships to expand its product offerings and global reach. With a commitment to improving patient lives, Aspen continues to drive innovation and deliver quality healthcare solutions globally.
Aspen Pharmacare Holdings Ltd, a leading pharmaceutical company, has achieved several significant milestones. Over the years, the company has expanded its global presence and diversified its product portfolio. It has successfully acquired and integrated multiple companies, enhancing its market reach and capabilities. Aspen Pharmacare has also developed and launched innovative medicines, contributing to advancements in healthcare. The company has received numerous industry awards and recognition, further highlighting its commitment to excellence. With a strong focus on research and development, Aspen Pharmacare continues to make substantial contributions to the healthcare industry, delivering high-quality solutions to patients worldwide.
Aspen Pharmacare Holdings Ltd is primarily present in various countries and regions worldwide. Some of the key markets where the company operates include South Africa, where it is headquartered, as well as other African countries such as Kenya, Nigeria, and Ethiopia. Additionally, Aspen Pharmacare has a significant presence in Latin American countries including Brazil and Mexico. The company has also expanded its operations into Europe, with a focus on countries like Germany, Spain, Italy, and the United Kingdom. Furthermore, Aspen Pharmacare has a presence in the Asia-Pacific region, including Australia, China, and India.
Aspen Pharmacare Holdings Ltd represents a strong set of values and a clear corporate philosophy. The company aims to provide affordable medicines of high quality to people around the world, thus improving their health and well-being. Aspen Pharmacare values integrity, innovation, and accountability in all aspects of its operations. It focuses on sustainable growth and strategic partnerships to expand its global presence and reach. Aspen Pharmacare is committed to providing access to essential healthcare solutions and ensuring patient safety. With its dedicated workforce and commitment to excellence, Aspen Pharmacare continues to make a positive impact in the pharmaceutical industry.
Analisten hanteren momenteel een gemiddeld koersdoel van 120,02 ZAR voor het aandeel Aspen Pharmacare Holdings (mediaan: 117,30 ZAR), oftewel -27,0 % ten opzichte van de laatste koers. De consensus is gebaseerd op 10 analistenratings.
Aspen Pharmacare Holdings Koersdoelstellingen analisten 2026
10 analisten beoordelen het aandeel Aspen Pharmacare Holdings momenteel: 0 adviseren kopen, 6 houden en 4 verkopen.
Aspen Pharmacare Holdings Koersdoelstellingen analisten 2026
Omgezet tegen de huidige wisselkoers noteert het aandeel Aspen Pharmacare Holdings op 8,84 EUR (164,45 ZAR).
Het aandeel Aspen Pharmacare Holdings (APN.JO) is genoteerd aan 5 beurzen, waaronder: JSE (Johannesburg) (APN.JO), Frankfurt (LDZA.F), München (LDZA.MU), Düsseldorf (LDZA.DU).
Aspen Pharmacare Holdings Ltd is an international pharmaceutical company based in South Africa. The company specializes in the production and distribution of pharmaceuticals, biopharmaceuticals, and active ingredients. It is one of the largest manufacturers of generics in Africa. The company's business model is characterized by intensive R&D work and a strong presence in Africa. It produces a wide range of pharmaceutical products for various fields such as psychiatry, oncology, gastroenterology, and pain therapy. Aspen is also a significant provider of veterinary medicines. One of the key aspects of its business model is the production of generics, offering cost-effective alternatives to branded products. This allows Aspen to establish a strong presence and achieve high market penetration in markets with limited investment requirements. The company has expanded its business in Europe and Asia, in addition to its strong presence in Africa. This geographical diversification allows Aspen to reach a broad customer base and minimize risks. Besides its products, Aspen also offers tailored services such as shipping, storage, and logistics management to ensure fast and efficient delivery to customers. The company has also expanded its presence in biopharmaceuticals through the acquisition of ThromboGenics in 2013, making it a leading provider of platelet activating factors. Aspen is committed to social responsibility and has initiated various initiatives to improve access to affordable medical products in Africa. Overall, Aspen Pharmacare Holdings Ltd's business model is based on its wide range of products and services, strategic focus on the African market, and effective implementation of its strategy, which has made it one of the largest and fastest-growing pharmaceutical companies in Africa.
De omzet van Aspen Pharmacare Holdings bedraagt 34,87 Miljard ZAR. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De winst van Aspen Pharmacare Holdings bedraagt 2,65 Miljard ZAR. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Aspen Pharmacare Holdings bedraagt momenteel 27,55. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Aspen Pharmacare Holdings-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Aspen Pharmacare Holdings bedraagt momenteel 2,09. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Aspen Pharmacare Holdings-aandeel.
De Eulerpool Kwaliteitsscore voor Aspen Pharmacare Holdings is 1/10.
De ISIN van Aspen Pharmacare Holdings is ZAE000066692. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Aspen Pharmacare Holdings is A0ET80. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Aspen Pharmacare Holdings is APN.JO. Onder dit beurstickersymbool wordt het Aspen Pharmacare Holdings-aandeel op de beurs verhandeld.
Aspen Pharmacare Holdings aandeel
Aspen Pharmacare Holdings Peer Group
Aspen Pharmacare Holdings Ticker
Aspen Pharmacare Holdings FIGI
Alle fundamentals en diepgaande analyse van Aspen Pharmacare Holdings
Onze aandelenanalyse van het Aspen Pharmacare Holdings-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Aspen Pharmacare Holdings. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: